Sarah Boyce - Mar 8, 2024 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
President and CEO, Director
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Stock symbol
RNA
Transactions as of
Mar 8, 2024
Transactions value $
-$2,291,512
Form type
4
Date filed
3/12/2024, 05:29 PM
Previous filing
Mar 5, 2024
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $104K +84K +74.92% $1.24* 196K Mar 8, 2024 Direct F1
transaction RNA Common Stock Sale -$1.8M -84K -42.83% $21.39 112K Mar 8, 2024 Direct F1, F2
transaction RNA Common Stock Options Exercise $34.7K +28K +24.97% $1.24* 140K Mar 12, 2024 Direct F1
transaction RNA Common Stock Sale -$634K -28K -19.98% $22.63 112K Mar 12, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -84K -8.29% $0.00 929K Mar 8, 2024 Common Stock 84K $1.24 Direct F4
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -28K -3.01% $0.00 901K Mar 12, 2024 Common Stock 28K $1.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan.
F2 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.33 to $21.54. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.61 to $22.71. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 All unexercised shares subject to the option are fully vested and exercisable as of the date hereof.